key: cord-0870240-s3xy3kpa
authors: Kow, Chia Siang; Aldeyab, Mamoon; Hasan, Syed Shahzad
title: Quality of adverse event reporting in clinical trials of remdesivir in patients with COVID-19
date: 2020-10-04
journal: Eur J Clin Pharmacol
DOI: 10.1007/s00228-020-03008-6
sha: b5d30811986b67b1633e2dc0eca4fd63816f3067
doc_id: 870240
cord_uid: s3xy3kpa

nan

Remdesivir appears to be promising in the treatment of novel coronavirus disease 2019 . However, the evaluation of the effectiveness of remdesivir should be done in parallel with the analysis of its adverse events since only little is known about its safety. In fact, the reporting of a case of symmetrical drug-related intertriginous and flexural exanthema related to the administration of remdesivir in a patient with COVID-19 by Heck et al. [1] indicates a risk signal on the use of this newly approved agent. The medical community is heavily relying on the clinical trials to inform the possible harms of remdesivir. We undertake the evaluation of the quality of adverse event (AE) reporting in clinical trials [2] [3] [4] [5] of remdesivir in patients with COVID-19 based on adherence to the recommendations from the extension of the Consolidated Standards of Reporting Trials (CONSORT) statement for better reporting of harms [6] . However, there are multiple items of interest within a single CONSORT harms recommendation, and thus scoring the multiple items within a single recommendation would be difficult and misleading. Therefore, we employed the validated methods by Hadi et al. [7] to split each single CONSORT harms recommendation into two or three items resulting in a 19-item checklist. Each item of the 19-item checklist was scored individually and weighted with equal importance in line with CONSORT recommendations. Each item carries a score of '1' if it was adequately reported or '0' if it was not adequately reported or not reported at all. The total harm reporting score was calculated by summing up all the individual scores, where the total harm reporting score could range from 0 (worst possible score) to 19 (best possible score). Based on the total harm reporting score, we classified the quality of reporting of the adverse event into 'high' (score of 15-19), moderate (score of 10-14), low (score of 5-9), and very low (score 0-4).

The adequacy of the three clinical trials of remdesivir in COVID-19 fulfilling each of the CONSORT harms recommendations is presented in Table 1 . The trial by Wang et al. , the potential of remdesivir to cause acute hepatotoxicity which was not detected in the clinical trials was also recently discovered in a case report [8] . We urge that future and ongoing clinical trials on remdesivir in COVID-19 should follow the ten CONSORT harm recommendations in terms of reporting adverse events for a better understanding of the safety of remdesivir in its use in COVID-19 patients. This is of utmost importance such that the potential clinical benefits of remdesivir are not negated by the development of adverse events in susceptible patients.

Conflict of interest The authors declare that they have no conflict of interest. 

Remdesivir for 5 or 10 days in patients with severe Covid-19

Effect of remdesivir vs standard care on clinical status at 11 days in patients with moderate COVID-19: A Randomized Clinical Trial

Better reporting of harms in randomized trials: an extension of the CONSORT statement

Quality of reporting of harms in randomised controlled trials of pharmacological interventions for rheumatoid arthritis: a systematic review

Drug-induced liver injury in a COVID-19 patient: potential interaction of remdesivir with P-glycoprotein inhibitors

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations